OCSOculis Holding AG Ordinary shares
About Oculis Holding AG Ordinary shares
Oculis (NASDAQ:OCS) focuses on developing ophthalmic treatments that aim to improve the sight and lives of patients globally. Their innovative projects include therapies for conditions like diabetic macular edema and dry eye disease, showcasing a dedication to addressing major eye health challenges. Oculis' objectives revolve around pushing the boundaries of science to create effective, accessible treatments. With a commitment to leveraging cutting-edge technology and research, the company works tirelessly to bring new solutions to the forefront of eye care.
What is OCS known for?
Snapshot
Public US
Ownership
2016
Year founded
38
Employees
Zug, Switzerland
Head office
1 of 3
US Rank
Unknown
Sector
N/A
Sector rank
Loading Map...
Operations
All Locations
Switzerland
Products and/or services of Oculis Holding AG Ordinary shares
- A topical eye drop treatment aiming to reduce the progression of diabetic retinopathy and prevent vision loss.
- An innovative solution for treating dry eye disease, enhancing patient comfort and reducing symptoms.
- A non-invasive therapy for age-related macular degeneration to improve visual acuity and slow disease progression.
- A novel eye drop for the treatment of anterior uveitis, aiming to reduce inflammation and pain without the side effects of current therapies.
- A groundbreaking solution for patients with glaucoma, focusing on reducing intraocular pressure through a non-surgical approach.
- A breakthrough therapy for the treatment of corneal edema, offering patients rapid relief and improved vision.
Oculis Holding AG Ordinary shares executive team
- Dr. Riad Sherif M.B.A., M.D.CEO & Director
- Ms. Sylvia CheungChief Financial Officer
- Ms. Gudrun Bachmann Ph.D.Chief Technology Officer
- Dr. Ramin Tadayoni M.D., Ph.D.Chief Scientific Officer
- Mr. Daniel S. Char J.D.Chief Legal Officer
- Ms. Virginia R. DeanChief Human Resources Officer
- Mr. Páll Ragnar JóhannessonChief Business Officer
- Ms. Rebecca Weil Ph.D.Chief Commercial Officer
- Dr. Snehal Shah Pharm.D.President of Research & Development
- Dr. Sharon Klier M.D., M.P.H.Chief Development Officer